Scott’s Directories

FEBRUARY 24, 2022

When dealing with medical sales, utilizing a Canadian Doctors Directory is a sure way to generate new clients. There are a few ways to help boost these sales and remain competitive. What is B2B Medical Sales? B2B is a term that refers to sales between two businesses. billion by the end of 2025, from $196.3

Medical sales 52

Medical sales Medical Sales Doctors 52

Quantified

SEPTEMBER 21, 2023

Part of that growth comes from using AI tools for professional work, especially sales. According to Gartner, 75% of B2B sales organizations will augment traditional playbooks with AI by 2025 despite the current low adoption rate. Competitive pressure will drive companies to invest in AI tools for sales.

Sales 52

Sales Prospecting Training Sales tools 52

Rep-Lite

JULY 27, 2023

In today’s fast-evolving world, the medical sales industry stands at the forefront of innovation, with medical devices playing a pivotal role in patient care and treatment. The demand for these life-saving technologies continues to surge, presenting an exciting opportunity for growth and success in medical device sales.

Sales 52

Sales Medical Medical sales Sales Strategy 52

Sales Talent

FEBRUARY 7, 2020

**The 2022 Sales Hiring Forecast has been released – check it out now!**. It’s time for the 6th installment of our annual sales hiring forecast. As there isn’t a hiring forecast specific for b2b sales roles, we started our own forecast in 2015 to help fill this gap. 2019 Sales Hiring in Review. 2020 Sales Hiring Forecast.

Sales 52

Sales B2B Sales Recruitment Marketing 52

Quantified

MAY 5, 2022

Since the pandemic disrupted in-person sales interactions, sales organizations have had to shift their strategies without much supporting technology. McKinsey found that 80-90% of sales are now done remotely. They can leverage advanced, AI-based software when building a remote sales team that’s effective and efficient.

Training 52

Training Sales Management Sales pitches 52

Pharmaceutical Technology

MAY 19, 2023

EyePoint Pharmaceuticals will also receive potential royalties on the combined net sales of Iluvien and Yutiq in the US from 2025 to 2028. The company made a $75m up-front cash payment to EyePoint Pharmaceuticals on the closure of the deal, and an additional $7.5m will be paid in equal quarterly instalments in 2024.

Food and Drug Administration 52

Food and Drug Administration Food Pharmaceutical Sales 52

pharmaphorum

SEPTEMBER 21, 2022

AZ and partner Amgen – which makes the drug and records commercial sales for the drug in the US – are hoping to build a market for the drug as an alternative to current biologics for severe asthma, which can only be prescribed to patients with specific biomarkers. billion or more.

Sales 106

Sales Biopharma Medicine Patients 106

Pharmaceutical Technology

MAY 19, 2023

AbbVie anticipates Rinvoq sales to exceed $7.5bn in 2025 and for the peak revenues from both drugs to exceed Humira’s peak sales by 2027.

Food and Drug Administration 105

Food and Drug Administration FDA Sales Food 105

European Pharmaceutical Review

NOVEMBER 2, 2023

Stelara biosimilars in the US market The first Stelara biosimilars are expected to enter the US market in 2025. “We US sales of Stelara totalled $6.4 We do not expect entry of Stelara biosimilars in the United States during 2024,” Joseph Wolk CFO, Johnson & Johnson, stated during the company’s Q3 earnings call on 18 October.

Food and Drug Administration 87

Food and Drug Administration FDA Side effects Safety 87

European Pharmaceutical Review

APRIL 18, 2023

Camlipixant, a novel P2X3 antagonist, has the potential to be a best-in-class treatment with significant sales potential,” Miels added. According to GSK, the P2X3 antagonist has the potential to deliver significant sales through 2031 and beyond. Data is anticipated in H2 2024 and 2025, respectively. per share in cash.

Biopharma 81

Biopharma Sales Patients Medical 81

Pharmaceutical Technology

JUNE 7, 2023

In addition, Mounjaro is estimated to gain sales of around $20bn by 2030 and become the leading GLP-1 in the obesity market, as well as in T2D. In 2022, Lilly reported sales for Mounjaro were approximately $500m, but this is expected to increase significantly in 2023 due to strong demand for the T2D drug.

Leads 98

Leads Marketing FDA Sales 98

World of DTC Marketing

JULY 17, 2022

Novo Nordisk more than doubled its sales targets for obesity drugs to $3.7bn by 2025. Unpaid celebrity endorsements include venture capitalist Marc Andreessen, who says the drug completely changed his relationship with food, and Elon Musk, who has cited it on Twitter. Its share price has risen 26 percent in the past year.

Side effects 209

Side effects Insurance Doctors Prescription 209

Pharmaceutical Technology

JANUARY 30, 2023

According to GlobalData’s Drugs database, there were 22 prophylactic vaccines in development for COVID-19 with sales forecasts available in H2 2022. According to GlobalData’s Drugs database, there were 22 prophylactic vaccines in development for COVID-19 with sales forecasts available in H2 2022.

Sales 52

Sales Competition Leads Medicine 52

pharmaphorum

DECEMBER 22, 2022

The first vaccines are due to be produced at the new facility in 2025. Moderna has previously announced deals to build research units in Australia and Canada since its coffers were swelled by COVID-19 vaccine sales, and has also said it is planning to build a $500 million manufacturing plant in Africa.

Government 118

Government Manufacturing Sales Medicine 118

Pharmaceutical Technology

JANUARY 19, 2023

Zelenoleucel is being evaluated in the Phase II ARTEMIS trial, and if it demonstrates a benefit over the standard of care arm, it could reach the US market as early as 2025. If approved, it could reach sales of $158 million in the 8MM (US, France, Germany, Italy, Spain, the UK, Japan, and China) by 2031.

Marketing 52

Marketing FDA Sales Management 52

pharmaphorum

SEPTEMBER 9, 2022

Novo Nordisk can be credited with re-invigorating the market for obesity drug therapies with its GLP-1 agonist therapies – Saxenda (liraglutide) and Wegovy (semaglutide) – which collectively saw sales increase 84% to $950 million, despite some supply constraints for Wegovy. Novo Nordisk recently predicted its obesity sales could reach $3.7

Pharmacology 91

Pharmacology Patients Management Consulting 91

Contrarian Sales Techniques

FEBRUARY 24, 2023

The Green Technology Financing Scheme (GTFS) is improved, with the guaranteed value increased to RM3 billion until 2025. The period of the Green Investment Tax Allowance and Green Income Tax Exemption is extended until December 31, 2025. RM100 million allocated for Jualan Rahmah sales in all Parliamentary constituencies.

Government 52

Government Education Medical sales reps Food 52

Clarivate

JANUARY 23, 2024

forecast peak sales per asset versus the cost of developing an asset or an output measure such as the number of global first world launches). In addition, R&D productivity analyses are in some way associated with actual or future launches or a consequence of the launch, such as resulting sales.

Pharma 52

Pharma Sales Consulting Pharmaceutical 52

pharmaphorum

OCTOBER 26, 2022

The drug was highlighted at Boehringer’s R&D update earlier this year as one of the most promising candidates among 15 new medicines it plans to bring to market by 2025, fuelled by a €25 billion R&D spend. First approved back in 2014, it is still growing strongly, with its 2021 sales of €2.5

Recruitment 93

Recruitment Prospecting Marketing Patients 93

pharmaphorum

JANUARY 9, 2023

Additionally, its top-selling drug, Myalept or Myalepta, had third-quarter sales of $37.9m. The development is for expansion of the company’s in-house drug development of biologicals and rare disease targeting and the site is due to become operational from 2024, with FDA, IFA, and EMA approvals due to be sought for 2025.

Pharma 84

Pharma Biopharma Management Medicine 84

Pharmaceutical Technology

APRIL 21, 2023

GlobalData anticipated mirikizumab to be approved in the US in 2023, but this recent development may push mirikizumab back behind other agents such as Skyrizi and Tremfya, which are anticipated to enter the US market in 2024 and 2025, respectively. in 2031 while mirikizumab is expected to reach US sales of $318.2m

Manufacturing 52

Manufacturing FDA Medicine Sales 52

Legacy MEDSearch

JULY 7, 2023

The company is expected to continue its strong growth trajectory with an estimated three-year CAGR of around 30% until FY 2025/26 EBIT margin assumptions 2) : Kerecis’ EBIT margin is expected to be around 10% in FY 2022/23 and to continue expanding to around 20% in FY 2025/26.

Recruitment 52

Recruitment Management Medical Networking 52

Pharmaceutical Technology

OCTOBER 31, 2022

Two categories of novel therapies stand out: cell therapies and therapies with novel MOAs, with new products in each category being forecast to launch between 2023 and 2025. These are forecast to contribute significantly towards sales in the OA market in 2031, accounting for 10% and 14.2% of the 7MM sales, respectively.

Marketing 59

Marketing Sales Patients Competition 59

pharmaphorum

DECEMBER 4, 2022

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist Wegovy (semaglutide), which the company reckons will drive its obesity sales to $3.7 billion in 2025 once initial manufacturing problems are resolved.

Manufacturing 76

Manufacturing FDA Sales Marketing 76

pharmaphorum

NOVEMBER 2, 2022

.” The deal also ties in with J&J’s plan to boost the margins it makes from its medical device and pharma divisions as it prepares to spin off its slower-growing consumer health business before the end of 2023 and chases down target revenues of $60 billion in 2025. Impella heart pump. Joaquin Duato.

Sales 52

Sales Medical Manufacturing Marketing 52

pharmaphorum

JANUARY 10, 2023

Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. It flows from every direction in torrents to create huge opportunities to address the world’s mounting health issues.

Marketing 98

Marketing Pharma Healthcare Healthcare 98

pharmaphorum

AUGUST 17, 2022

Additional payments will be tied to specific research, development, and sales milestones. A recent report from GlobalData predicted that pharma spending on AI drug discovery would hit $3 billion in 2025. That same report noted that the number of companies in the AI drug discovery space increased tenfold between 2015 and 2021.

Medicine 78

Medicine Pharma Engineering Sales 78

pharmaphorum

SEPTEMBER 20, 2022

Patents for denosumab expired in some European markets in June, although the drug is still protected in France, Italy, Spain, and the UK until 2025, when exclusivity also comes to an end in the US market. The company recorded sales of $3.25 billion for the drug last year, two thirds from the US market.

Medicine 52

Medicine Safety Marketing Biopharma 52

LEVO Health

NOVEMBER 30, 2021

In 2020, social commerce sales were estimated at almost 27 billion dollars in the United States. By 2025, social commerce sales are expected to reach 79.6 As the global pandemic raged on and in-person shopping plummeted due to social distancing measures, social media platforms became a go-to shopping outlet.

Media 52

Media Healthcare Healthcare Marketing 52

Clarivate

DECEMBER 7, 2021

Indeed, millennial consumers are expected to drive 50% of luxury goods purchases by 2025. [1]. Asia’s increasing prominence – in the region’s contribution to luxury sales and where highest number of actions and cases are filed by luxury brands occur – impact luxury brands’ domain management strategies.

Professional Services 95

Professional Services Management Competition Sales 95

pharmaphorum

AUGUST 9, 2022

It is AZ’s biggest-selling drug, with sales topping $5 billion last year. The pairing of Tagrisso with savolitinib has now started a phase 3 trial called SAFFRON , which will compare the duo with chemotherapy in EGFR-positive NSCLC with MET mutations, with results due in 2025.

Patients 52

Patients FDA Sales Marketing 52

Pharmaceutical Technology

JULY 21, 2022

Pharma giant AstraZeneca also plans to make its supply chain carbon-negative by 2030; to reduce its Scope 1 emissions by 20%, Scope 2 emissions by 95%, and Scope 3 emissions by 25% per $1m of sales by 2025. Access to medication. Improving access could save ten million lives each year, four million in Africa and Southeast Asia.

Government 52

Government Healthcare Healthcare Pharma 52

CloserIQ

DECEMBER 14, 2018

We’ve compiled some of our favorite reads to help you advance in your sales career and build top sales teams. Once you hire the right people, you’ll train them on your sales process and then put them on the phones. The holidays are here, and you’re probably wondering what gifts to buy for your sales representatives. .

Sales 60

Sales Sales pipeline Sales process Recruitment 60

PM360

SEPTEMBER 21, 2023

Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall. The IRA sets physician reimbursement of these products at the CMS-established MFP plus 6% versus current average sales price.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

pharmaphorum

SEPTEMBER 11, 2022

Analysts at Mizuho have suggested that competition from BMS’ drug could trim Otezla’s 2025 sales from $3 billion to $2 billion, although Amgen is attempting to defend its product by expanded the label of the drug to include mild psoriasis. Otezla was acquired by Amgen for $13.4

FDA 52

FDA Marketing Sales Patients 52

Integrity Solutions

NOVEMBER 19, 2018

According to an Ernst & Young study , millennials will comprise 75% of the global workforce by 2025. As a millennial myself, I take on my sales role with great ambition and achievement drive, ready to contribute, but there are also things that I know what I want from my company. The question is, will they want to work for you?

Training 76

Training Sales Management Leads 76

Pharmaceutical Technology

SEPTEMBER 2, 2022

Yet despite this promising data, it’s a well-known fact that drug launches are under-performing – with around two-thirds of new drugs successfully navigating the long and rocky approval process only to fall drastically short of their pre-launch sales expectations.

Food and Drug Administration 52

Food and Drug Administration Pharma Medicine Distribution 52